Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Receivables: 2010-2024

Historic Receivables for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $944,000.

  • Altimmune's Receivables rose 112.23% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 17.26%. This contributed to the annual value of $944,000 for FY2024, which is 22.05% down from last year.
  • Latest data reveals that Altimmune reported Receivables of $944,000 as of FY2024, which was down 22.05% from $1.2 million recorded in FY2023.
  • In the past 5 years, Altimmune's Receivables ranged from a high of $4.6 million in FY2020 and a low of $173,000 during FY2022.
  • Over the past 3 years, Altimmune's median Receivables value was $944,000 (recorded in 2024), while the average stood at $776,000.
  • Its Receivables has fluctuated over the past 5 years, first crashed by 90.69% in 2021, then surged by 600.00% in 2023.
  • Over the past 5 years, Altimmune's Receivables (Yearly) stood at $4.6 million in 2020, then tumbled by 90.69% to $429,000 in 2021, then plummeted by 59.67% to $173,000 in 2022, then spiked by 600.00% to $1.2 million in 2023, then fell by 22.05% to $944,000 in 2024.